#United States #Bethesda #Glioblastoma #Northwest Biotherapeutics #DCVax-L

Groundbreaking Survival Data from Northwest Biotherapeutics

In a significant development for glioblastoma treatment, Northwest Biotherapeutics (OTCQB:NWBO) has unveiled updated survival data stemming from its Phase III trial of DCVax-L. The recent findings were presented by the company's Chief Technical Officer, Dr. Marnix Bosch, during the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS). This data, derived from individual patient-level analyses across multiple independent reviews, indicates that the survival advantages observed in earlier assessments were understated.

Methodology of Analysis

The original analysis utilized cohort-level data to compare outcomes between patients treated with DCVax-L and control subjects. However, the study has recently gained access to individual patient data (IPD) from substantial randomized controlled trials (RCTs) focused on newly diagnosed glioblastoma (ndGBM). This has enabled more precise comparisons, allowing for refined analyses of the therapeutic impact of DCVax-L.

Two robust statistical approaches were applied by independent statisticians to analyze the data: Propensity Score Matching (PSM) and Inverse Probability Weighting (IPW). In PSM analyses of two major RCTs involving ndGBM, the median survival advantage from DCVax-L treatment was found to be between 4.9 and 6.3 months. Furthermore, a third RCT demonstrated a survival edge of 3.4 to 3.7 months. The Hazard Ratios (HRs) calculated ranged from 0.69 to 0.77, with significance values (p values) between 0.004 and 0.027, all indicating a substantial improvement over the previously recorded median survival advantage of 2.8 months.

IPW analyses, taking another methodological route, yielded comparable findings, showing a median survival advantage of 3.4 to 4.3 months.

Sensitivity Analyses

In addition to PSM and IPW evaluations, sensitivity analyses were conducted to scrutinize potential confounding variables. These analyses utilized E Values and Rosenbaum's Gamma statistics to test the reliability of the observed treatment effects, confirming that the improvements in survival rates were not due to hidden biases between the DCVax-L patients and the controls.

“Together, the PSM and IPW analyses reinforce the survival benefits associated with DCVax-L treatment,” stated Dr. Bosch. “The consistency across various independent analyses strengthens our confidence that the initial survival benefit reported was significantly underestimated.”

About Northwest Biotherapeutics

Northwest Biotherapeutics is focused on developing personalized immune therapies aimed at treating cancers in a more effective manner than traditional therapies, minimizing toxic side effects often associated with standard chemotherapy. The flagship program emphasizes the DCVax-L treatment for glioblastoma, which stands as one of the most aggressive brain cancers currently recognized and is categorized as an orphan disease. With a completed Phase III trial involving 331 patients, results have been disseminated in reputable scientific venues, including JAMA Oncology. Moreover, a Marketing Authorization Application (MAA) for the product has been filed in the UK and is presently under review.

Beyond DCVax-L, the company is advancing its research on DCVax-Direct, which targets inoperable solid tumor cancers and is poised for further Phase II trials following successful Phase I outcomes.

As the field of cancer treatment continues to evolve, Northwest Biotherapeutics’ innovative approaches provide hope for improved patient outcomes and a pathway toward effective therapies that leverage the body's own immune system.

For further details, you can access the full presentation on the company's official website at www.nwbio.com.